AQST Q3 2022 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$11M-13.7% YoY

Gross Profit

$7M59.7% margin

Operating Income

-$9M-77.2% margin

Net Income

-$13M-109.4% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

-13.6%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$1M

Stock-Based Comp.

$535,000

Balance Sheet

Total Assets

$52M

Total Liabilities

$160M

Stockholders' Equity

-$108M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$13M	-13.7%
Gross Profit	$7M	$9M	-23.1%
Operating Income	-$9M	-$8M	-11.1%
Net Income	-$13M	-$15M	+13.9%

Revenue Segments

Manufacture and Supply Revenue

$8M73%

Proprietary Product Sales

$2M20%

Co-Development and Research Fees

$395,0003%

License and Royalty Revenue

$376,0003%

Geographic Segments

UNITED STATES

$9M79%

Non-US

$2M21%